A Novel Potential Role for Monocytes Revealed by Single Cell Analysis of Immunotherapy Induced Immune Related Adverse Events
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
3. Results
3.1. PBMC Population Dynamics
3.2. Immune Cell Population Shifts
3.3. GSEA Pathway Analysis
3.3.1. Healthy Control PBMCs Compared to Cancer PBMCs
3.3.2. Mild vs. Severe irAE States
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Fujii, T.; Colen, R.R.; Bilen, M.A.; Hess, K.R.; Hajjar, J.; Suarez-Almazor, M.E.; Alshawa, A.; Hong, D.S.; Tsimberidou, A.; Janku, F.; et al. Incidence of immune-related adverse events and its association with treatment outcomes: The MD Anderson Cancer Center experience. Investig. New Drugs 2018, 36, 638–646. [Google Scholar] [CrossRef] [PubMed]
- Komiya, K.; Nakamura, T.; Abe, T.; Ogusu, S.; Nakashima, C.; Takahashi, K.; Kimura, S.; Sueoka-Aragane, N. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac. Cancer 2018, 10, 1798–1804. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schneider, B.J.; Naidoo, J.; Santomasso, B.D.; Lacchetti, C.; Adkins, S.; Anadkat, M.; Atkins, M.B.; Brassil, K.J.; Caterino, J.M.; Chau, I.; et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J. Clin. Oncol. 2016, 39, 4073–4126. [Google Scholar] [CrossRef] [PubMed]
- Lozano, A.X.; Chaudhuri, A.A.; Nene, A.; Bacchiocchi, A.; Earland, N.; Vesely, M.D.; Usmani, A.; Turner, B.E.; Steen, C.B.; Luca, B.A.; et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat. Med. 2022, 28, 353–362. [Google Scholar] [CrossRef]
- Waickman, A.T.; Friberg, H.; Gromowski, G.D.; Rutvisuttinunt, W.; Li, T.; Siegfried, H.; Victor, K.; McCracken, M.K.; Fernandez, S.; Srikiatkhachorn, A.; et al. Temporally integrated single cell RNA sequencing analysis of PBMC from experimental and natural primary human DENV-1 infections. PLoS Pathog. 2021, 17, e1009240. [Google Scholar] [CrossRef]
- Navegantes, K.C.; de Souza Gomes, R.; Pereira, P.A.T.; Czaikoski, P.G.; Azevedo, C.H.M.; Monteiro, M.C. Immune modulation of some autoimmune diseases: The critical role of macrophages and neutrophils in the innate and adaptive immunity. J. Transl. Med. 2017, 15, 36. [Google Scholar] [CrossRef] [Green Version]
- Kim, K.H.; Hur, J.Y.; Cho, J.; Ku, B.M.; Koh, J.; Koh, J.Y.; Sun, J.-M.; Lee, S.-H.; Ahn, J.S.; Park, K.; et al. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology 2020, 9, 1722023. [Google Scholar] [CrossRef] [Green Version]
- Subudhi, S.K.; Aparicio, A.; Gao, J.; Zurita, A.J.; Araujo, J.C.; Logothetis, C.J.; Tahir, S.A.; Korivi, B.R.; Slack, R.S.; Vence, L.; et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc. Natl. Acad. Sci. USA 2016, 113, 11919–11924. [Google Scholar] [CrossRef] [Green Version]
- Sasson, S.C.; Slevin, S.M.; Cheung, V.T.; Nassiri, I.; Olsson-Brown, A.; Fryer, E.; Ferreira, R.C.; Trzupek, D.; Gupta, T.; Al-Hillawi, L.; et al. Interferon-Gamma–Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor–Colitis. Gastroenterology 2021, 161, 1229–1244.e9. [Google Scholar] [CrossRef]
- De Coaña, Y.P.; Wolodarski, M.; Poschke, I.; Yoshimoto, Y.; Yang, Y.; Nyström, M.; Edbäck, U.; Brage, S.E.; Lundqvist, A.; Masucci, G.V.; et al. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget 2017, 8, 21539–21553. [Google Scholar] [CrossRef]
- Reschke, R.; Gussek, P.; Boldt, A.; Sack, U.; Köhl, U.; Lordick, F.; Gora, T.; Kreuz, M.; Reiche, K.; Simon, J.-C.; et al. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy. Int. J. Mol. Sci. 2021, 22, 8017. [Google Scholar] [CrossRef]
- Romee, R.; Schneider, S.E.; Leong, J.W.; Chase, J.M.; Keppel, C.R.; Sullivan, R.P.; Cooper, M.A.; Fehniger, T.A. Cytokine activation induces human memory-like NK cells. Blood 2012, 120, 4751–4760. [Google Scholar] [CrossRef] [Green Version]
- Bielekova, B.; Catalfamo, M.; Reichert-Scrivner, S.; Packer, A.; Cerna, M.; Waldmann, T.A.; McFarland, H.; Henkart, P.A.; Martin, R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA 2006, 103, 5941–5946. [Google Scholar] [CrossRef] [Green Version]
- Saraste, M.; Irjala, H.; Airas, L. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol. Sci. 2007, 28, 121–126. [Google Scholar] [CrossRef]
- Shibatomi, K.; Ida, H.; Yamasaki, S.; Nakashima, T.; Origuchi, T.; Kawakami, A.; Migita, K.; Kawabe, Y.; Tsujihata, M.; Anderson, P.; et al. A novel role for interleukin-18 in human natural killer cell death: High serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Arthritis Rheum 2001, 44, 884–892. [Google Scholar] [CrossRef]
- Benczur, M.; Petrányl, G.G.; Pálffy, G.; Varga, M.; Tálas, M.; Kotsy, B.; Földes, I.; Hollán, S.R. Dysfunction of natural killer cells in multiple sclerosis: A possible pathogenetic factor. Clin. Exp. Immunol. 1980, 39, 657–662. [Google Scholar]
- Kastrukoff, L.F.; Lau, A.; Wee, R.; Zecchini, D.; White, R.; Paty, D.W. Clinical relapses of multiple sclerosis are associated with ‘novel’ valleys in natural killer cell functional activity. J. Neuroimmunol. 2003, 145, 103–104. [Google Scholar] [CrossRef]
- Winkler-Pickett, R.; Young, H.A.; Cherry, J.M.; Diehl, J.; Wine, J.; Back, T.; Bere, W.E.; Mason, A.T.; Ortaldo, J.R. In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: Alteration of primary adaptive responses. J. Immunol. 2008, 180, 4495–4506. [Google Scholar] [CrossRef] [Green Version]
- Olingy, C.E.; Dinh, H.; Hedrick, C.C. Monocyte heterogeneity and functions in cancer. J. Leukoc. Biol. 2019, 106, 309–322. [Google Scholar] [CrossRef] [Green Version]
- Mukherjee, R.; Barman, P.K.; Thatoi, P.K.; Tripathy, R.; Das, B.K.; Ravindran, B. Non-Classical monocytes display inflammatory features: Validation in Sepsis and Systemic Lupus Erythematous. Sci. Rep. 2015, 5, 13886. [Google Scholar] [CrossRef] [Green Version]
- Burbano, C.; Vasquez, G.; Rojas, M. Modulatory Effects of CD14+CD16++ Monocytes on CD14++CD16− Monocytes: A Possible Explanation of Monocyte Alterations in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2014, 66, 3371–3381. [Google Scholar] [CrossRef] [PubMed]
- Chavan, R.; Salvador, D.; Gustafson, M.P.; Dietz, A.B.; Nevala, W.; Markovic, S.N. Untreated Stage IV Melanoma Patients Exhibit Abnormal Monocyte Phenotypes and Decreased Functional Capacity. Cancer Immunol. Res. 2014, 2, 241–248. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Thomas, M.F.; Slowikowski, K.; Manakongtreecheep, K.; Sen, P.; Tantivit, J.; Nasrallah, M.; Smith, N.P.; Ramesh, S.; Zubiri, L.; Tirard, A.; et al. Altered interactions between circulating and tissue-resident CD8 T cells with the colonic mucosa define colitis associated with immune checkpoint inhibitors. bioRxiv 2021. online ahead of print. [Google Scholar] [CrossRef]
- Smallwood, M.J.; Nissim, A.; Knight, A.R.; Whiteman, M.; Haigh, R.; Winyard, P.G. Oxidative stress in autoimmune rheumatic diseases. Free Radic. Biol. Med. 2018, 125, 3–14. [Google Scholar] [CrossRef] [PubMed]
- Frossi, B.; De Carli, M.; Piemonte, M.; Pucillo, C. Oxidative microenvironment exerts an opposite regulatory effect on cytokine production by Th1 and Th2 cells. Mol. Immunol. 2008, 45, 58–64. [Google Scholar] [CrossRef] [PubMed]
- Kawakami, T.; Koike, A.; Maehara, T.; Hayashi, T.; Fujimori, K. Bicarbonate enhances the inflammatory response by activating JAK/STAT signalling in LPS + IFN-γ-stimulated macrophages. J. Biochem. 2020, 167, 623–631. [Google Scholar] [CrossRef]
- Wittmann, C.; Chockley, P.; Singh, S.K.; Pase, L.; Lieschke, G.; Grabher, C. Hydrogen Peroxide in Inflammation: Messenger, Guide, and Assassin. Adv. Hematol. 2012, 2012, 541471. [Google Scholar] [CrossRef]
- Rao, X.; Zhong, J.; Sun, Q. The heterogenic properties of monocytes/macrophages and neutrophils in inflammatory response in diabetes. Life Sci. 2014, 116, 59–66. [Google Scholar] [CrossRef] [Green Version]
- Nauseef, W.; Borregaard, N. Neutrophils at work. Nat. Immunol. 2014, 15, 602–611. [Google Scholar] [CrossRef]
- Takano, T.; Azuma, N.; Satoh, M.; Toda, A.; Hashida, Y.; Satoh, R.; Hohdatsu, T. Neutrophil survival factors (TNF-alpha, GM-CSF, and G-CSF) produced by macrophages in cats infected with feline infectious peritonitis virus contribute to the pathogenesis of granulomatous lesions. Arch. Virol. 2009, 154, 775–781. [Google Scholar] [CrossRef]
Age (Years) | Sex | Metastatic Melanoma Subtype | ICI Regimen | Highest irAE Grade | Time to irAE or Follow-Up (Months) | Gastro-Intestinal (GI) irAE Status | ICI Response Status | Total Follow-Up Time (Months) |
---|---|---|---|---|---|---|---|---|
72 | Male | Acral | Ipilimumab + Nivolumab | 3 | 0.39 | No | no durable benefit | 9.36 |
66 | Male | Sun-exposed | Ipilimumab + Nivolumab | 1 | 14.85 | No | durable clinical benefit | 14.95 |
80 | Female | Sun-exposed | Anti-PD1 | 0 | 18.37 | No | not evaluable | 18.37 |
39 | Male | Indeterminate | Ipilimumab + Nivolumab | 0 | 13.34 | No | no durable benefit | 13.34 |
Cell Type | Healthy Control | irAE 0 | irAE 1 | irAE 3 | Log Fold Change (Healthy–0) | Log Fold Change (0–1) | Log Fold Change (1–3) |
---|---|---|---|---|---|---|---|
Naïve B | 2.865 | 11.60 | 7.915 | 6.196 | 2.02 | −0.55 | −0.35 |
CD14+ Monocyte | 14.93 | 21.48 | 43.09 | 30.07 | 0.52 | 1.00 | −0.52 |
CD16+ Monocyte | 1.684 | 11.72 | 8.040 | 15.06 | 2.80 | −0.54 | 0.91 |
CD4+ T Central Memory | 35.32 | 26.59 | 21.98 | 26.54 | −0.41 | −0.27 | 0.27 |
CD8+ T Effector Memory | 12.55 | 0.3927 | 0.1256 | 0.1270 | −5.00 | −1.64 | 0.02 |
Natural Killer Cell | 3.057 | 23.72 | 18.22 | 14.02 | 2.96 | −0.38 | −0.38 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Garrison, Z.; Chang, M.; Hornick, N.; Yu, W.Y.; Cheng, J.B.; Kulkarni, R.P. A Novel Potential Role for Monocytes Revealed by Single Cell Analysis of Immunotherapy Induced Immune Related Adverse Events. Cancers 2022, 14, 5407. https://doi.org/10.3390/cancers14215407
Garrison Z, Chang M, Hornick N, Yu WY, Cheng JB, Kulkarni RP. A Novel Potential Role for Monocytes Revealed by Single Cell Analysis of Immunotherapy Induced Immune Related Adverse Events. Cancers. 2022; 14(21):5407. https://doi.org/10.3390/cancers14215407
Chicago/Turabian StyleGarrison, Zachary, Matthew Chang, Noah Hornick, Wesley Y. Yu, Jeffrey B. Cheng, and Rajan P. Kulkarni. 2022. "A Novel Potential Role for Monocytes Revealed by Single Cell Analysis of Immunotherapy Induced Immune Related Adverse Events" Cancers 14, no. 21: 5407. https://doi.org/10.3390/cancers14215407